R&D Spending Showdown: Bristol-Myers Squibb Company vs Wave Life Sciences Ltd.

R&D Spending: Big Pharma vs. Biotech

__timestampBristol-Myers Squibb CompanyWave Life Sciences Ltd.
Wednesday, January 1, 201445340000002395000
Thursday, January 1, 201559200000009057000
Friday, January 1, 2016494000000040818000
Sunday, January 1, 2017641100000079309000
Monday, January 1, 20186345000000134428000
Tuesday, January 1, 20196148000000175431000
Wednesday, January 1, 202011143000000130944000
Friday, January 1, 202110195000000121875000
Saturday, January 1, 20229509000000115856000
Sunday, January 1, 20239299000000130009000
Monday, January 1, 202411159000000
Loading chart...

Unleashing insights

A Decade of R&D: Bristol-Myers Squibb vs. Wave Life Sciences

In the ever-evolving landscape of pharmaceutical innovation, research and development (R&D) spending is a critical indicator of a company's commitment to future growth. Over the past decade, Bristol-Myers Squibb Company (BMY) and Wave Life Sciences Ltd. (WVE) have demonstrated contrasting approaches to R&D investment.

From 2014 to 2023, Bristol-Myers Squibb consistently allocated substantial resources to R&D, with expenditures peaking in 2020 at over 11 billion dollars. This represents a staggering 145% increase from their 2014 spending. In contrast, Wave Life Sciences, a smaller player, saw its R&D expenses grow from a modest 2.4 million dollars in 2014 to approximately 130 million dollars in 2023, marking an impressive 5,300% increase.

These figures highlight the diverse strategies of a pharmaceutical giant and an emerging biotech firm, each navigating the complex path of drug discovery and development.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025